Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2260-2267

  Dowsett, Mitch ^a   Dixon, J Michael ^b   Horgan, Kieran ^c   Salter, Janine ^a   Hills, Margaret ^a   Harvey, Eileen ^d  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b Edinburgh Breast Unit   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; IDOXIFENE; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PLACEBO; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NICK END LABELING; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; APOPTOSIS; BIOLOGICAL MARKERS; BIOPSY; BREAST NEOPLASMS; CELL DIVISION; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TIME FACTORS;

EID: 0034122595     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Johnston, S. R. D., Gumbrell, L., Evan, T. R. J., Coleman, R. E., Smith, I. E., Rea, D., Soukop, M., Howell, A., Jones, A., Dowsett, M., and Coombes, R. C. A phase II randomized double-blind study of idoxifene (40mg/d) vs tamoxifen (40mg/d) in patients with locally advanced metastatic breast cancer resistant to tamoxifen (20mg/d). Proc. Am. Soc. Clin. Oncol., 18: 109a, 1999.
2. Coombes, R. C., Haynes, B. P., Dowsett, M., Quigley, M., English, J., Judson, I. R., Griggs, L. J., Potter, G. A., McCague, R., and Jarman, M. Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Res., 55: 1070-1074, 1995.
3. Chander, S. K., McCague, R., Luqmani, Y., and Coombes, R. C. Pyrrolidino-4-iodotamoxifen and 4-tamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res., 51: 5851-5858, 1991.
4. Delmas, P. D., Mulder, H., Eastell, R., Greenwald, M., and MacDonald, B. Idoxifene reduces bone turnover in osteopenic postmenopausal women. Bone, 23: S494, 1998.
5. Mulder, H., Wasnich, R., and Eastell, R. The effects of idoxifene on markers of cardiovascular risk in osteopenic postmenopausal women. Eur. Heart J., 19: 237, 1998.
6. Clarke, R. B., Laidlaw, I. J., Jones, L. J., Howell, A., and Anderson, E. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to estrogen and progesterone receptor status. Br. J. Cancer, 67: 606-611, 1993.
7. De Friend, D. J., Howell, A., Nicholson, R. I., Anderson, E., Dowsett, M., Mansel, R. E., Blamey, R. W., Bundred, N. J., Robertson, J. F., Saunders, C., Baum, M., Walton, P., Sutcliffe, F., and Wakeling, A. E. Investigation of a new pure anti-estrogen (ICI 182780) in women with primary breast cancer. Cancer Res., 54: 408-414, 1994.
8. Makris, A, Powles, T. J., Allred, D. C., Ashley, S. E., Ormerod, M. G., Titley, J. C., and Dowsett, M. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Br. Cancer Res. Treat., 48: 11-20, 1998.
9. Ellis, P. A., Saccani-Jotti, G., Clarke, R., Johnston, S. R. D., Anderson, E., Howell, A., A'Hern, R., Salter, J., Detre, S., Nicholson, R., Robertson, J., Baum, M., Smith, I. E., and Dowsett, M. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int. J. Cancer, 72: 608-613, 1997.
10. Kyprianou, N., English, H. F., Davidson, N. E., and Isaacs, J. T. Programmed cell death during regression of the MCF human breast cancer following oestrogen ablation. Cancer Res., 51: 162-166, 1991.
11. Detre, S., Salter, J., Barnes, D. M., Riddler, S., Hills, M., Johnston, S., Gillett, C., A'Hern, R., and Dowsett, M. Time-related effects of oestrogen withdrawal on proliferation and cell death-related events in MCF7 xenografts. Int. J. Cancer, 81: 309-313, 1999.
12. Johnston, S. R. D, Boeddinghaus, I. M., Riddler, S., Haynes, B. P., Hardcastle, I. R., Jarman, M., and Dowsett, M. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Cancer Res., 59: 3646-3651, 1999.
13. Henderson, I. C. Endocrine therapy of metastatic breast cancer. In: J. R. Harris, S. Hellman, I. C. Henderson, and D. W. Kinne (eds.), Breast Diseases, 2nd Ed., pp. 559-603. Philadelphia: J. B. Lippincott, 1991.
14. Ellis, P. A., Smith, I. E., Detre, S., Burton, S. A., Salter, J., A'Hern, R., Walsh, G., Johnston, S. R. D, and Dowsett, M. Reduced apoptosis and proliferation and increased bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res. Treat., 48: 107-116, 1998.
15. Bevitt, D. J., Milton, I. D., Pigott, N., Henry, L., Carter, M. J., Tonas, G. L., Leonard, T. W., Westley, B., Angus, B., and Home, C. H. New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry. J. Pathol., 183: 228-232, 1997.
16. Wenger, C. R., Beardslee, S., Owens, M. A., Pounds, G., Oldaker, T., Vendeley, P., Pandian, M. R., Harrington, D., Clark, G. M., and McGuire, W. L. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res. Treat., 28: 9-20, 1993.
17. Bardon, S., Vignon, F., Montcourrier, P., and Rocheport, H. Steroid receptor medicated cytotoxicity of an anti-estrogen and an anti-progestin in breast cancer cells. Cancer Res., 47: 1441-1448, 1987.
18. Warri, A. M., Huovinen, R. L., Laine, A. M., Martikanine, P. M., and Harkonen, P. L. Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J. Natl. Cancer Inst., 85: 1412-1418, 1993.
19. Dowsett, M., Johnston, S. R. D., Detre, S., Salter, J., Humphries, S., Saccani, G-J., Smith, I. E., MacLennan, K., and Trott, P. Cytological evaluation of biological variables in breast cancer patients undergoing primary medical treatment. In: M. Motta and M. Serio (eds.), Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects, pp. 329-336. Amsterdam: Elsevier Science BV, 1994.
20. Metzger, D., Berry, M., Ali, S., and Chambon, P. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo. Mol. Endocrinol., 9: 579-591, 1995.
21. Nawaz, Z., Lonard, D. M., Dennis, A. P., Smith, C. L., and O'Malley, B. W. Proteasome-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. USA, 96: 1858-1862, 1999.
22. Horwitz, K. B., Yoseki, Y., and McGuire, W. L. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology, 103: 1742-1751, 1978.
23. Howell, A., Harland, R. N. L., Barnes, D. M., Baildam, A. D., Wilkinson, M. J., Hayward, E., Swindell, R., and Sellwood, R. A. Endocrine therapy for advanced carcinoma of the breast: effect of tumor heterogeneity and site of biopsy on the predictive value of progesterone receptor estimations. Cancer Res., 47: 296-299, 1987.
24. Noguchi, S., Miyauchi, K., Nishizawa, Y., and Koyama, H. Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time. Cancer (Phila.), 61: 1345-1349, 1988.